1. Home
  2. SRPT
  3. SRPT News

Latest Sarepta Therapeutics Inc. (DE) (SRPT) News on June 2, 2025

1 Value Stock on Our Buy List and 2 to Approach with Caution
SRPT

StockStory

10 hours ago

1 Value Stock on Our Buy List and 2 to Approach with Caution

1 Volatile Stock to Own for Decades and 2 to Keep Off Your Radar
SRPT

StockStory

3 days ago

1 Volatile Stock to Own for Decades and 2 to Keep Off Your Radar

Was Jim Cramer Right About Sarepta Therapeutics Inc. (SRPT)?
SRPT

Insider Monkey

6 days ago

Was Jim Cramer Right About Sarepta Therapeutics Inc. (SRPT)?

FDA advisers pan Pfizer’s PARP drug; Sarepta to resume Duchenne study
SRPT

BioPharma Dive

11 days ago

FDA advisers pan Pfizer’s PARP drug; Sarepta to resume Duchenne study

Sarepta Therapeutics (NasdaqGS:SRPT) Continues Phase 3 Study of ELEVIDYS Gene Therapy in Duchenne
SRPT

Simply Wall St.

12 days ago

Sarepta Therapeutics (NasdaqGS:SRPT) Continues Phase 3 Study of ELEVIDYS Gene Therapy in Duchenne

SRPT

MT Newswires

12 days ago

Sarepta Therapeutics Says Dosing to Continue in UK Trial of Duchenne Muscular Dystrophy Treatment

Sarepta Provides Update on UK Dosing in ENVISION Study of ELEVIDYS for the treatment of Duchenne Muscular Dystrophy
SRPT

Business Wire

12 days ago

Sarepta Provides Update on UK Dosing in ENVISION Study of ELEVIDYS for the treatment of Duchenne Muscular Dystrophy

High Growth Tech Stocks In The US Market To Watch
SRPT

Simply Wall St.

13 days ago

High Growth Tech Stocks In The US Market To Watch

3 Stocks Investors May Be Undervaluing By Up To 43.5%
SRPT

Simply Wall St.

13 days ago

3 Stocks Investors May Be Undervaluing By Up To 43.5%

SRPT Q1 Earnings Call: Sarepta Adjusts Guidance After Safety Event and Administrative Delays
SRPT

StockStory

14 days ago

SRPT Q1 Earnings Call: Sarepta Adjusts Guidance After Safety Event and Administrative Delays

Sarepta reports outcomes from trial of Duchenne muscular dystrophy therapy
SRPT

Clinical Trials Arena

14 days ago

Sarepta reports outcomes from trial of Duchenne muscular dystrophy therapy

Sarepta Therapeutics Shares New Protein Expression and Safety Results from ENDEAVOR in Participants 2 Years Old at Time of Treatment
SRPT

Business Wire

17 days ago

Sarepta Therapeutics Shares New Protein Expression and Safety Results from ENDEAVOR in Participants 2 Years Old at Time of Treatment

Sarepta Therapeutics Presents Data at the American Society of Gene & Cell Therapy Conference, Including Statistically Significant Functional Outcomes for 8- and 9-Year-Old Patients in New Data Analysis of EMBARK Part 2
SRPT

Business Wire

17 days ago

Sarepta Therapeutics Presents Data at the American Society of Gene & Cell Therapy Conference, Including Statistically Significant Functional Outcomes for 8- and 9-Year-Old Patients in New Data Analysis of EMBARK Part 2

2 Healthcare Stocks to Keep an Eye On and 1 to Ignore
SRPT

StockStory

18 days ago

2 Healthcare Stocks to Keep an Eye On and 1 to Ignore

Bearish: Analysts Just Cut Their Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Revenue and EPS estimates
SRPT

Simply Wall St.

19 days ago

Bearish: Analysts Just Cut Their Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Revenue and EPS estimates

Q1 Therapeutics Earnings: United Therapeutics (NASDAQ:UTHR) Impresses
SRPT

StockStory

19 days ago

Q1 Therapeutics Earnings: United Therapeutics (NASDAQ:UTHR) Impresses

SRPT

Argus Research

20 days ago

SRPT: Lowering target price to $29.00

SRPT

MT Newswires

20 days ago

Sarepta Therapeutics Says Duchenne Muscular Dystrophy Treatment Gets Approval in Japan

Sarepta Therapeutics Announces Approval in Japan of ELEVIDYS, a Gene Therapy to Treat Duchenne Muscular Dystrophy
SRPT

Business Wire

20 days ago

Sarepta Therapeutics Announces Approval in Japan of ELEVIDYS, a Gene Therapy to Treat Duchenne Muscular Dystrophy

2 Stocks Near Their 52-Week Lows That Still Aren't Worth Buying
SRPT

Motley Fool

20 days ago

2 Stocks Near Their 52-Week Lows That Still Aren't Worth Buying

Sarepta Therapeutics, Inc. (SRPT): Among Billionaire Glenn Russell Dubin’s Stock Picks with Huge Upside Potential
SRPT

Insider Monkey

22 days ago

Sarepta Therapeutics, Inc. (SRPT): Among Billionaire Glenn Russell Dubin’s Stock Picks with Huge Upside Potential

Trump announces trade deal, BoE lowers Bank Rate: Morning Buzz
SRPT

TipRanks

24 days ago

Trump announces trade deal, BoE lowers Bank Rate: Morning Buzz

Is Sarepta Therapeutics, Inc. (SRPT) The Best Stock That Will Bounce Back?
SRPT

Insider Monkey

24 days ago

Is Sarepta Therapeutics, Inc. (SRPT) The Best Stock That Will Bounce Back?

Sarepta Therapeutics to Present at the BofA Securities Health Care Conference
SRPT

Business Wire

25 days ago

Sarepta Therapeutics to Present at the BofA Securities Health Care Conference

Sarepta price target lowered to $125 from $183 at Needham
SRPT

TipRanks

25 days ago

Sarepta price target lowered to $125 from $183 at Needham

SRPT

MT Newswires

25 days ago

UBS Cuts Price Target on Sarepta Therapeutics to $85 From $188, Keeps Buy Rating

Sarepta Therapeutics First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
SRPT

Simply Wall St.

25 days ago

Sarepta Therapeutics First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

Why Sarepta Therapeutics, Inc. (SRPT) Nosedived on Wednesday
SRPT

Insider Monkey

25 days ago

Why Sarepta Therapeutics, Inc. (SRPT) Nosedived on Wednesday

Q1 Earnings Recap: AbbVie (NYSE:ABBV) Tops Therapeutics Stocks
SRPT

StockStory

25 days ago

Q1 Earnings Recap: AbbVie (NYSE:ABBV) Tops Therapeutics Stocks

Therapeutics Stocks Q1 Results: Benchmarking Sarepta Therapeutics (NASDAQ:SRPT)
SRPT

StockStory

25 days ago

Therapeutics Stocks Q1 Results: Benchmarking Sarepta Therapeutics (NASDAQ:SRPT)

The 'Double Whammy' That Sent Sarepta Stock To An Eight-Year Low
SRPT

Investor's Business Daily

a month ago

The 'Double Whammy' That Sent Sarepta Stock To An Eight-Year Low

Sarepta Therapeutics (SRPT) Stock Trades Down, Here Is Why
SRPT

StockStory

a month ago

Sarepta Therapeutics (SRPT) Stock Trades Down, Here Is Why

Sarepta Therapeutics Stock Plunges on Guidance Cut. Its ‘Moneymaker’ Is Under Fire.
SRPT

Barrons.com

a month ago

Sarepta Therapeutics Stock Plunges on Guidance Cut. Its ‘Moneymaker’ Is Under Fire.

SRPT

Thomson Reuters StreetEvents

a month ago

Q1 2025 Sarepta Therapeutics Inc Earnings Call

SRPT Q1 Earnings Miss, Sales Beat, Stock Slides 21% on '25 View Cut
SRPT

Zacks

a month ago

SRPT Q1 Earnings Miss, Sales Beat, Stock Slides 21% on '25 View Cut

Sarepta shares fall amid FDA’s CBER appointment and weak Elevidys sales
SRPT

Pharmaceutical Technology

a month ago

Sarepta shares fall amid FDA’s CBER appointment and weak Elevidys sales

Sarepta Therapeutics Inc (SRPT) Q1 2025 Earnings Call Highlights: Robust Revenue Growth Amidst ...
SRPT

GuruFocus.com

a month ago

Sarepta Therapeutics Inc (SRPT) Q1 2025 Earnings Call Highlights: Robust Revenue Growth Amidst ...

Compared to Estimates, Sarepta Therapeutics (SRPT) Q1 Earnings: A Look at Key Metrics
SRPT

Zacks

a month ago

Compared to Estimates, Sarepta Therapeutics (SRPT) Q1 Earnings: A Look at Key Metrics

Sarepta Therapeutics (NASDAQ:SRPT) Surprises With Q1 Sales But Stock Drops 22.8%
SRPT

StockStory

a month ago

Sarepta Therapeutics (NASDAQ:SRPT) Surprises With Q1 Sales But Stock Drops 22.8%

Sarepta Therapeutics (SRPT) Reports Q1 Loss, Tops Revenue Estimates
SRPT

Zacks

a month ago

Sarepta Therapeutics (SRPT) Reports Q1 Loss, Tops Revenue Estimates

SRPT

MT Newswires

a month ago

Sarepta Therapeutics Swings to Non-GAAP Q1 Loss; Shares Tumble After Hours

Earnings To Watch: Sarepta Therapeutics (SRPT) Reports Q1 Results Tomorrow
SRPT

StockStory

a month ago

Earnings To Watch: Sarepta Therapeutics (SRPT) Reports Q1 Results Tomorrow

Oppenheimer Predicts Up to ~840% Surge for These 2 ‘Strong Buy’ Stocks
SRPT

TipRanks

a month ago

Oppenheimer Predicts Up to ~840% Surge for These 2 ‘Strong Buy’ Stocks

1 of Wall Street’s Favorite Stock on Our Buy List and 2 to Approach with Caution
SRPT

StockStory

a month ago

1 of Wall Street’s Favorite Stock on Our Buy List and 2 to Approach with Caution

Geron (GERN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
SRPT

Zacks

a month ago

Geron (GERN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Why Sarepta Therapeutics, Inc. (SRPT) is Among the Best Oversold NASDAQ Stocks to Buy Right Now
SRPT

Insider Monkey

a month ago

Why Sarepta Therapeutics, Inc. (SRPT) is Among the Best Oversold NASDAQ Stocks to Buy Right Now

Sarepta Therapeutics (SRPT) Reports Next Week: Wall Street Expects Earnings Growth
SRPT

Zacks

a month ago

Sarepta Therapeutics (SRPT) Reports Next Week: Wall Street Expects Earnings Growth

Sarepta Therapeutics (SRPT): Among Billionaire George Soros’ Small-Cap Stocks with Huge Upside Potential
SRPT

Insider Monkey

a month ago

Sarepta Therapeutics (SRPT): Among Billionaire George Soros’ Small-Cap Stocks with Huge Upside Potential

SRPT

Argus Research

a month ago

SRPT: Raising target price to $47.00

Sarepta Therapeutics to Announce First Quarter 2025 Financial Results
SRPT

Business Wire

a month ago

Sarepta Therapeutics to Announce First Quarter 2025 Financial Results

Is Sarepta Therapeutics, Inc. (SRPT) the Most Promising Long-Term Stock According to Analysts?
SRPT

Insider Monkey

a month ago

Is Sarepta Therapeutics, Inc. (SRPT) the Most Promising Long-Term Stock According to Analysts?

Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost
SRPT

Investor's Business Daily

a month ago

Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost

Exploring 3 High Growth Tech Stocks In The US Market
SRPT

Simply Wall St.

a month ago

Exploring 3 High Growth Tech Stocks In The US Market

SRPT

MT Newswires

2 months ago

BofA Adjusts Price Target on Sarepta Therapeutics to $157 From $179, Keeps Buy Rating

Sarepta Therapeutics (NASDAQ:SRPT investor one-year losses grow to 54% as the stock sheds US$166m this past week
SRPT

Simply Wall St.

2 months ago

Sarepta Therapeutics (NASDAQ:SRPT investor one-year losses grow to 54% as the stock sheds US$166m this past week

SRPT Provides Pipeline Updates on Rare Muscular Disorder Therapies
SRPT

Zacks

2 months ago

SRPT Provides Pipeline Updates on Rare Muscular Disorder Therapies

Unpacking Q4 Earnings: AbbVie (NYSE:ABBV) In The Context Of Other Therapeutics Stocks
SRPT

StockStory

2 months ago

Unpacking Q4 Earnings: AbbVie (NYSE:ABBV) In The Context Of Other Therapeutics Stocks

SRPT

Argus Research

2 months ago

SRPT: Raising target price to $44.00

Sarepta Therapeutics Announces Pipeline Progress for Multiple Limb-Girdle Muscular Dystrophy Programs
SRPT

Business Wire

2 months ago

Sarepta Therapeutics Announces Pipeline Progress for Multiple Limb-Girdle Muscular Dystrophy Programs

SRPT

MT Newswires

2 months ago

Wells Fargo Initiates Sarepta Therapeutics at Overweight With $115 Price Target

The Zacks Analyst Blog Highlights Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb
SRPT

Zacks

2 months ago

The Zacks Analyst Blog Highlights Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb

Biotech Stock Roundup: PCRX Up on Patent News, EWTX Down on Study Data & More
SRPT

Zacks

2 months ago

Biotech Stock Roundup: PCRX Up on Patent News, EWTX Down on Study Data & More

SRPT

Argus Research

2 months ago

SRPT: Lowering target price to $39.00

3 Reasons to Avoid SRPT and 1 Stock to Buy Instead
SRPT

StockStory

2 months ago

3 Reasons to Avoid SRPT and 1 Stock to Buy Instead

SRPT

MT Newswires

2 months ago

Oppenheimer Adjusts Price Target on Sarepta Therapeutics to $184 From $215, Keeps Outperform Rating

4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall Street
SRPT

Motley Fool

2 months ago

4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall Street

Sarepta and Roche aim to resume paused Elevidys trials following patient death
SRPT

Clinical Trials Arena

2 months ago

Sarepta and Roche aim to resume paused Elevidys trials following patient death

Sarepta Therapeutics Stock Falls as Some Trials Halted After Patient Death
SRPT

Investopedia

2 months ago

Sarepta Therapeutics Stock Falls as Some Trials Halted After Patient Death

SRPT

MT Newswires

2 months ago

Sarepta Says EU Regulators Temporarily Halt Enrollment, Dosing in Elevidys Trials

Sarepta price target lowered to $183 from $202 at Needham
SRPT

TipRanks

2 months ago

Sarepta price target lowered to $183 from $202 at Needham

Sarepta Therapeutics Provides Update on ELEVIDYS
SRPT

Business Wire

2 months ago

Sarepta Therapeutics Provides Update on ELEVIDYS

SRPT Stock Down After EMA Places Clinical Hold on DMD Gene Therapy
SRPT

Zacks

2 months ago

SRPT Stock Down After EMA Places Clinical Hold on DMD Gene Therapy

Sarepta Dives On 'Another Unfortunate Development' For Its Gene Therapy
SRPT

Investor's Business Daily

2 months ago

Sarepta Dives On 'Another Unfortunate Development' For Its Gene Therapy

Sarepta/Roche Suspend Elevidys Gene Therapy Trials In Europe After Patient Death
SRPT

Benzinga

2 months ago

Sarepta/Roche Suspend Elevidys Gene Therapy Trials In Europe After Patient Death

SRPT

MT Newswires

2 months ago

Sarepta Shares Fall After EMA Reportedly Places Hold on Elevidys Trial Enrollment for Duchenne Muscular Dystrophy

Sarepta Plunges After EMA Puts Gene Therapy Studies On Hold Following Teen's Death
SRPT

Investor's Business Daily

2 months ago

Sarepta Plunges After EMA Puts Gene Therapy Studies On Hold Following Teen's Death

SRPT

MT Newswires

2 months ago

Deutsche Bank Adjusts Sarepta Therapeutics Price Target to $70 From $99, Maintains Hold Rating

Roche halts testing of Sarepta Duchenne gene therapy in Europe
SRPT

BioPharma Dive

2 months ago

Roche halts testing of Sarepta Duchenne gene therapy in Europe

Q4 Earnings Outperformers: Amgen (NASDAQ:AMGN) And The Rest Of The Therapeutics Stocks
SRPT

StockStory

2 months ago

Q4 Earnings Outperformers: Amgen (NASDAQ:AMGN) And The Rest Of The Therapeutics Stocks

SRPT

MT Newswires

2 months ago

Sarepta Therapeutics Shares Rise After HC Wainwright Upgrade

SRPT

MT Newswires

2 months ago

HC Wainwright Upgrades Sarepta Therapeutics to Neutral From Sell, Price Target is $75

SRPT

Argus Research

2 months ago

SRPT: Lowering target price to $50.00

Sarepta price target lowered to $179 from $210 at BofA
SRPT

TipRanks

2 months ago

Sarepta price target lowered to $179 from $210 at BofA

Rocket acquires Mr. Cooper, Musk’s xAI acquires X: Morning Buzz
SRPT

TipRanks

2 months ago

Rocket acquires Mr. Cooper, Musk’s xAI acquires X: Morning Buzz

Biotech stocks slide as Marks resignation seen being negative for sector
SRPT

TipRanks

2 months ago

Biotech stocks slide as Marks resignation seen being negative for sector

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SRPT

Business Wire

2 months ago

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Biotechs Hammered After FDA Official Resigns, Citing RFK Jr.'s 'Misinformation And Lies'
SRPT

Investor's Business Daily

2 months ago

Biotechs Hammered After FDA Official Resigns, Citing RFK Jr.'s 'Misinformation And Lies'

Why Sarepta Therapeutics (SRPT) Stock Is Nosediving
SRPT

StockStory

2 months ago

Why Sarepta Therapeutics (SRPT) Stock Is Nosediving

SRPT

MT Newswires

2 months ago

Sarepta Therapeutics Faces Uncertainty Amid FDA Changes, Patient Death, RBC Says

Biotech Investors Rush for the Exits After FDA Official Resigns: Heard on the Street
SRPT

The Wall Street Journal

2 months ago

Biotech Investors Rush for the Exits After FDA Official Resigns: Heard on the Street

Moderna, Vaxcyte, Novavax Hammered After Key FDA Official Peter Marks Resigns
SRPT

Investor's Business Daily

2 months ago

Moderna, Vaxcyte, Novavax Hammered After Key FDA Official Peter Marks Resigns

Moderna, Novavax Stocks Fall After Top FDA Vaccine Official Forced Out
SRPT

The Wall Street Journal

2 months ago

Moderna, Novavax Stocks Fall After Top FDA Vaccine Official Forced Out

SRPT

MT Newswires

2 months ago

RBC Downgrades Sarepta Therapeutics to Sector Perform From Outperform, Adjusts PT to $87 From $161

Is Sarepta Therapeutics (SRPT) the Best Mid Cap Biotech Stock to Buy?
SRPT

Insider Monkey

2 months ago

Is Sarepta Therapeutics (SRPT) the Best Mid Cap Biotech Stock to Buy?

Sarepta Therapeutics (SRPT) Down 30.3% Since Last Earnings Report: Can It Rebound?
SRPT

Zacks

2 months ago

Sarepta Therapeutics (SRPT) Down 30.3% Since Last Earnings Report: Can It Rebound?

SRPT

Argus Research

2 months ago

SRPT: What does Argus have to say about SRPT?

How to Play SRPT Stock After Patient Death Post DMD Therapy Infusion
SRPT

Zacks

2 months ago

How to Play SRPT Stock After Patient Death Post DMD Therapy Infusion

Q4 Rundown: Moderna (NASDAQ:MRNA) Vs Other Therapeutics Stocks
SRPT

StockStory

2 months ago

Q4 Rundown: Moderna (NASDAQ:MRNA) Vs Other Therapeutics Stocks

Is This Stock a Buy After a Massive 20% Drop in 1 Day?
SRPT

Motley Fool

2 months ago

Is This Stock a Buy After a Massive 20% Drop in 1 Day?

Q4 Earnings Review: Therapeutics Stocks Led by BioMarin Pharmaceutical (NASDAQ:BMRN)
SRPT

StockStory

2 months ago

Q4 Earnings Review: Therapeutics Stocks Led by BioMarin Pharmaceutical (NASDAQ:BMRN)

Share on Social Networks: